AbbVie jumps on the BCMA train, opting into TeneoOne buyAfter dipping its toe into the BCMA water with an option to codevelop a bispecific antibody developed by Share XAbbVie jumps on the BCMA train, opting into TeneoOne buyhttps://pharmaphorum.com/news/abbvie-jumps-on-the-bcma-train-opting-into-teneoone-buy/
FDA sets November review date for J&J’s multiple myeloma CAR-T cilta-celJohnson & Johnson has secured a six-month FDA review for its multiple myeloma CAR-T therapy ciltacabtagene autoleucel (cilta-cel), Share XFDA sets November review date for J&J’s multiple myeloma CAR-T cilta-celhttps://pharmaphorum.com/news/fda-sets-november-review-date-for-jjs-multiple-myeloma-car-t-cilta-cel/
Straight after its first cancer bispecific OK, J&J highlights two more at ASCOWith the ink barely dry on the FDA’s approval of Johnson & Johnson’s Rybrevant, its first bispecific antibody Share XStraight after its first cancer bispecific OK, J&J highlights two more at ASCOhttps://pharmaphorum.com/news/straight-after-its-first-cancer-bispecific-ok-jj-highlights-two-more-at-asco/
Janssen files its first CAR-T therapy cilta-cel in EuropeJohnson & Johnson’s Janssen unit has filed for approval of its multiple myeloma CAR-T ciltacabtagene autoleucel in Europe, Share XJanssen files its first CAR-T therapy cilta-cel in Europehttps://pharmaphorum.com/news/janssen-files-its-first-car-t-therapy-cilta-cel-in-europe/
Sanofi’s Sarclisa gains new US multiple myeloma indicationThe FDA has approved Sanofi’s Sarclisa (isatuximab) in combination with a new chemotherapy regimen for advanced multiple myeloma, Share XSanofi’s Sarclisa gains new US multiple myeloma indicationhttps://pharmaphorum.com/news/sanofis-sarclisa-gains-new-us-multiple-myeloma-indication/
FDA approves BMS’ multiple myeloma CAR-T AbecmaThe FDA has approved Bristol-Myers Squibb’s Abecma (idecabtagene vicleucel) for multiple myeloma, the first cell therapy to treat Share XFDA approves BMS’ multiple myeloma CAR-T Abecmahttps://pharmaphorum.com/news/fda-approves-bms-multiple-myeloma-car-t-abecma/
NICE backs ovarian cancer and multiple myeloma combination drugsNICE has recommended funding for two cancer drug combinations for ovarian cancer and multiple myeloma. In final draft Share XNICE backs ovarian cancer and multiple myeloma combination drugshttps://pharmaphorum.com/news/nice-backs-ovarian-cancer-and-multiple-myeloma-combination-drugs/
BCMA Targeted Therapies SummitBuilt with thought leaders from Seattle Genetics, Precision Biosciences and Kite Pharma, the inaugural industry-focused BCMA Targeted Therapies Share XBCMA Targeted Therapies Summithttps://pharmaphorum.com/events/bcma-targeted-therapies-summit/
NICE reverses stance on Celgene’s Revlimid for myeloma maintenanceNHS patients in England with newly-diagnosed multiple myeloma can be treated with Celgene’s Revlimid as maintenance therapy after Share XNICE reverses stance on Celgene’s Revlimid for myeloma maintenancehttps://pharmaphorum.com/news/nice-reverses-view-of-celgenes-revlimid-for-myeloma-maintenance/
